HR-756

Known as: HR 756, HR756 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1977-2003
024619772003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1981
1981
To measure the susceptibility of penicillin-resistant pneumococci to newer beta-lactam agents, we evaluated 54 selected strains… (More)
Is this relevant?
1981
1981
Cefodizime (HR221) is a new alpha-methoxyimino cephalosporin developed by Hoechst-Roussel with a reported serum half-life of over… (More)
Is this relevant?
1980
1980
The desacetyl metabolite (DES) of cefotaxime (HR756) is formed in vivo to a significant extent. The in vitro activities of DES… (More)
Is this relevant?
1980
1980
The in vitro antibacterial activity of HR-756 compared to cefoxitin and cefuroxime. 122 multiresistant clinical isolates… (More)
Is this relevant?
1980
1980
Moxalactam (LY127935) exhibited greater in vitro activity than cefamandole and tobramycin against clinical isolates of… (More)
Is this relevant?
1979
1979
The in vitro activity of HR 756, 7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoximino)acetamido] cephalosporanic acid, was investigated… (More)
Is this relevant?
1979
1979
The in vitro activity of HR 756 was compared with penicillin, cefamandole, cefoxitin, and tetracycline against Neisseria… (More)
Is this relevant?
1979
1979
HR 756, a new parenteral cephalosporin that is beta-lactamase resistant, was tested against 271 bacterial isolates. Both agar and… (More)
Is this relevant?
1978
1978
HR 756, a new parenteral cephalosporin, was compared with cefazolin and carbenicillin for activity against a total of 264 strains… (More)
Is this relevant?
1977
1977
HR 756 is a new cephalosporin derivative suitable for parenteral use. The compound possesses an unusally broad spectrum of… (More)
Is this relevant?